1452226-14-0

Basic information

• Product Name: 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid
• Synonyms: 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid
• CAS NO: 1452226-14-0
• Molecular Weight: 223.255
• Mol File: 1452226-14-0.mol

Chemical Properties

• CAS DataBase Reference: 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid(1452226-14-0)
• EPA Substance Registry System: 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid(1452226-14-0)

Safety Data

• Hazardous Substances Data: 1452226-14-0(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid is used as a building block for the synthesis of various pharmaceutical compounds due to its unique molecular structure and potential biological activities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid is used as a starting material for the development of new drugs, leveraging its potential to interact with biological targets and exhibit therapeutic effects.
Used in Drug Design:
5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid is utilized as a key component in the design of novel drug candidates, taking advantage of its structural features to optimize pharmacokinetic and pharmacodynamic properties.
Used in Chemical Synthesis:
In the field of organic chemistry, 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid serves as a versatile intermediate for the synthesis of a wide range of chemical compounds, including potential therapeutic agents and other specialty chemicals.
Used in Biochemical Studies:
5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid is employed as a research tool in biochemical studies to investigate its interactions with various biological molecules and to explore its potential as a modulator of biological processes.

Upstream product

• 1451998-35-8 methyl 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylate 
• 40380-36-7 5,6-dimethyl-3-oxo-2,3-dihydropyridazine-4-carbonitrile 
• 717840-40-9 ethyl 5-amino-3,4-dimethyl-thieno[2,3-c]pyridazine-6-carboxylate 
• 93824-72-7 3-chloro-5,6-dimethylpyridazine-4-carbonitrile 

Downstream Products

• 1451994-10-7 5-amino-N-(3-fluoro-4-methoxybenzyl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide 
• 1451996-10-3 C₁₉H₁₉FN₄O₂S 
• 1451995-73-5 C₁₈H₂₄N₄OS 
• 1451994-32-3 C₁₈H₁₈N₄OS 
• 1451994-31-2 C₂₀H₂₂N₄OS 
• 1451994-26-5 C₂₀H₂₂N₄OS 

Relevant articles and documents

Synthesis and Preliminary Evaluation of 11C-Labeled VU0467485/AZ13713945 and Its Analogues for Imaging Muscarinic Acetylcholine Receptor Subtype 4

Muscarinic acetylcholine receptors (mAChRs) have five distinct subunits (M1–M5) and are involved in the action of the neurotransmitter acetylcholine in the central and peripheral nervous system. Attributed to the promising clinical efficacy of xanomeline, an M1/M4-preferring agonist, in patients of schizophrenia and Alzheimer's disease, M1- or M4-selective mAChR modulators have been developed that target the topographically distinct allosteric sites. Herein we report the synthesis and preliminary evaluation of 11C-labeled positron emission tomography (PET) ligands based on a validated M4R positive allosteric modulator VU0467485 (AZ13713945) to facilitate drug discovery. [11C]VU0467485 and two other ligands were prepared in high radiochemical yields (>30 %, decay-corrected) with high radiochemical purity (>99 %) and high molar activity (>74 GBq μmol?1). In vitro autoradiography studies indicated that these three ligands possess moderate-to-high in vitro specific binding to M4R. Nevertheless, further physiochemical property optimization is necessary to overcome the challenges associated with limited brain permeability.

POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4

Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3, 2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.